MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Non-invasive Vagus Nerve Stimulation Alters Molecular Markers in Parkinson’s Disease Patients with Freezing of Gait

R. Banerjee, B. Mondal, S. Choudhury, A. Roy, K. Chatterjee, P. Basu, S. Baker, M. Baker, H. Kumar (Kolkata, India)

Meeting: 2023 International Congress

Abstract Number: 1496

Keywords: Inflammation, Neurostimulation, Parkinson’s

Category: Parkinson's Disease: Molecular Mechanisms of Disease

Objective: To investigate molecular mechanisms underlying non-invasive vagus nerve stimulation (nVNS) in Parkinson’s disease (PD) patients with freezing of gait (FOG).

Background: FOG remains one of the dopamine-resistant disabling gait abnormalities in PD. Neuromodulation with VNS may offer therapeutic benefit in FOG refractory to conventional treatment. In a cross-over trial, we observed that nVNS significantly improved motor symptoms in FOG patients. A key player in PD pathogenesis is neuroinflammation and there is growing evidence of involvement of peripheral inflammation. Since, VNS modulates inflammation, cervical nVNS might be useful in FOG treatment.

Method: Thirty-three PD patients with associated FOG were randomised to either nVNS or sham treatment. In this double-blind, sham-controlled trial, patients received six 2 min stimulations (total 12 min/day) of the nVNS/sham device (electroCore, Inc. USA) for one month. We measured selected neurotrophins, inflammatory markers and oxidative stress in serum, before and after stimulation. Inflammatory markers (TNF-α, IL-6, IL-10 and BDNF) were measured in serum by ELISA. Serum markers of oxidative stress, namely reduced glutathione and superoxide dismutase, were analysed by spectrophotometry.

Results: TNF-α levels were significantly reduced from baseline in patients receiving nVNS (28.1 to 23.5 pg/ml; p=0.028) but not in sham (23.2 to 24.7 pg/ml; p=0.499). The reduced glutathione concentration increased after nVNS (6.1 to 6.8 pg/ml; p=0.02) but did not change significantly after sham stimulation (6.7 to 6.1 pg/ml; p=0.05). BDNF levels significantly increased with the nVNS intervention (1946.7 to 2204.1 pg/ml; p=0.028) but decreased with sham stimulation (1943.7 to 1682.7 pg/ml; p=0.028). We did not find any significant differences in IL-6 (p=0.128), IL-10 (p=0.108) levels and the specific activity of superoxide dismutase between groups (p=0.058).

Conclusion: We provide the first evidence for the ability of nVNS to significantly reduce pro-inflammatory cytokines in PD patients and thereby indicate its anti-inflammatory mechanism. Increased serum BDNF also implicates neuroplastic changes by nVNS. The effects on antioxidant levels adds to its disease-modifying potential.

To cite this abstract in AMA style:

R. Banerjee, B. Mondal, S. Choudhury, A. Roy, K. Chatterjee, P. Basu, S. Baker, M. Baker, H. Kumar. Non-invasive Vagus Nerve Stimulation Alters Molecular Markers in Parkinson’s Disease Patients with Freezing of Gait [abstract]. Mov Disord. 2023; 38 (suppl 1). https://www.mdsabstracts.org/abstract/non-invasive-vagus-nerve-stimulation-alters-molecular-markers-in-parkinsons-disease-patients-with-freezing-of-gait/. Accessed November 1, 2026.
  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to 2023 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/non-invasive-vagus-nerve-stimulation-alters-molecular-markers-in-parkinsons-disease-patients-with-freezing-of-gait/

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley